Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from D. Boral Capital

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They presently have a $9.00 target price on the stock.

Other research analysts have also issued research reports about the stock. Morgan Stanley decreased their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, HC Wainwright lowered their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $7.89.

Invivyd Stock Performance

IVVD stock opened at $0.50 on Monday. Invivyd has a 52 week low of $0.38 and a 52 week high of $5.20. The company has a market capitalization of $59.21 million, a PE ratio of -0.25 and a beta of 0.64. The company’s 50-day simple moving average is $0.54 and its 200 day simple moving average is $0.86.

Insider Transactions at Invivyd

In related news, Director Terrance Mcguire sold 160,400 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the sale, the director now directly owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. This trade represents a 3.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders sold 816,466 shares of company stock valued at $423,214. Company insiders own 17.90% of the company’s stock.

Institutional Investors Weigh In On Invivyd

A number of hedge funds have recently made changes to their positions in IVVD. Proficio Capital Partners LLC acquired a new position in Invivyd during the 3rd quarter worth approximately $27,000. XTX Topco Ltd grew its stake in shares of Invivyd by 68.1% during the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after buying an additional 15,376 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Invivyd by 4,434.1% during the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after buying an additional 82,164 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Invivyd in the 2nd quarter valued at $115,000. Finally, Barclays PLC boosted its holdings in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after acquiring an additional 75,780 shares in the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.